Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01002755CT.gov Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphatic System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humax-Cd20 (this asset) | M.D. Anderson Cancer Center | P2 | B · 57 |
| Zilovertamab | Oncternal Therapeutics, Inc | P3 | B |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P2 | B |
| Bendamustine | UNC Lineberger Comprehensive Cancer Center | P2 | B |
| Ibrutinib | Oncternal Therapeutics, Inc | P3 | B |
| Lenalidomide | M.D. Anderson Cancer Center | P2 | B |
| Ex Vivo-Activated Autologous Lymph Node Lymphocytes | M.D. Anderson Cancer Center | P2 | B |
| LF-PB | Chemi S.p.A. | P2 | B |
| Jcar-017 Cd19-Specific Chimeric Antigen Receptor | Juno Therapeutics, a Subsidiary of Celgene | P2 | B |
+12 more in the Lymphatic System Disorder cohort
Other indications for Humax-Cd20
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BBB · 78 |
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Humax-Cd20 in Lymphatic System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/humax-cd20-lymphatic-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →